More recently, tocilizumab treatment was shown to reduce systemic inflammation (as measured by C-reactive protein), increase circulating lymphocyte levels, and reduce oxygen therapy needs in a trial of 20 patients with severe or critical COVID-19 (Xu et al. 2020). Here, CRP is linked to COVID-19.